MDMA therapy

What MDMA is

MDMA is a synthetic phenethylamine first patented by Merck in 1912 and rediscovered as a psychoactive compound in the 1970s by chemist Alexander Shulgin. Pharmacologically it is classified as an entactogen or empathogen: it triggers release of serotonin, dopamine, and norepinephrine, reliably producing elevated mood, increased interpersonal trust, and reduced fear response. Those properties are why MDMA is studied for PTSD — a disorder defined by a chronically over-active fear response that makes exposure-based therapy difficult to tolerate.

MDMA is not a classic serotonergic psychedelic like psilocybin or LSD. It does not primarily act at the 5-HT_2A receptor, and it does not produce the perceptual changes (visual imagery, ego dissolution) that those compounds do. It sits in its own category.

How MDMA-assisted therapy works

In the Phase 3 protocol used by MAPS / Lykos, treatment is three all-day dosing sessions, each 2–4 weeks apart, with one male and one female co-therapist in the room. Each session is 8 hours and is preceded by three preparation sessions and followed by three integration sessions (non-drug therapy). Total protocol: 12–18 therapy contacts over ~12 weeks.

The dose is typically 120–180 mg, with an optional supplemental half-dose ~90 minutes in. The therapy component is roughly "inner-directed": the therapists mostly let the patient lead, stepping in for structured check-ins, music transitions, and somatic work. This model is different from ketamine clinics, where the dosing is brief and the therapy is usually separate.

The FDA rejection: what actually happened

The FDA’s specific concerns, summarized from the CRL and the June 2024 FDA Psychopharmacologic Drugs Advisory Committee (which voted 9-2 and 10-1 against efficacy and benefit-risk):

• Functional unblinding. Participants who received MDMA almost always knew they had; placebo recipients usually knew they hadn’t. That breaks the double-blind and makes the placebo-controlled comparison weaker than the numbers suggest.
• Trial conduct concerns. Including allegations of boundary violations by therapists in earlier Phase 2 work, and concerns from MAPS-affiliated therapists about expectancy effects in the Phase 3 studies.
• Durability of effect. The CRL asked how long benefit actually lasts after the three-session protocol ends.
• Incomplete cardiac safety and lab data. The CRL noted gaps in liver analyte and electrolyte data from the Phase 3 trials and an incomplete cardiac safety assessment.¹

In October 2024 Lykos accepted the FDA’s view that the path forward requires a fresh Phase 3 trial and announced an independent third-party review of prior data. As of early 2026 there is no public resubmission date.²

What the evidence does support

PTSD — the core indication

Two published pivotal trials showed large treatment effects:

• MAPP1 (Mitchell et al., Nature Medicine 2021): In 90 participants with severe PTSD, after three MDMA-assisted sessions, 67% no longer met PTSD criteria versus 32% on placebo-assisted therapy.³
• MAPP2 (Mitchell et al., Nature Medicine 2023): In 104 participants — a more diverse population than MAPP1 — 71% of the MDMA arm no longer met PTSD criteria at 18 weeks versus 48% placebo.⁴

These effect sizes are among the largest ever reported for a PTSD pharmacotherapy. The FDA’s position is that the effect is real but the trials did not convincingly isolate it from expectancy and unblinding.

Other indications (exploratory)

• Alcohol use disorder: small open-label work at Imperial College London.
• Autism-related social anxiety: a single positive Phase 2 pilot (Danforth et al. 2018), not replicated at scale.
• Eating disorders / couples therapy: hypothesized, very limited data.

None of these have a Phase 3 program.

Safety & side effects

Serotonin syndrome is a life-threatening risk when MDMA is combined with SSRIs, SNRIs, MAOIs, or tramadol — trial protocols required tapering these medications before dosing. MDMA also has abuse liability (it is Schedule I) and has been associated with hyperthermia-related deaths in unregulated recreational settings.

Long-term neurotoxicity at therapeutic doses remains a subject of debate. Animal studies of very high repeated doses show serotonergic axon loss; clinical-dose trials have not demonstrated persistent cognitive effects, but the Phase 3 trials were not powered to detect subtle changes.

Legal status

MDMA is Schedule I in the United States: no accepted medical use, and research requires DEA Schedule I registration plus an FDA Investigational New Drug (IND) authorization. The August 2024 CRL did not change that status. MDMA goes by several street and colloquial names — ecstasy, Molly, X, E — but the legal status is the same regardless of terminology or form (pill, crystal, capsule).

Where is MDMA (Molly) legal?

Australia is the only country where MDMA can be legally prescribed, for PTSD, under the Therapeutic Goods Administration’s Authorised Prescriber scheme (since July 2023). The pathway requires individual patient approval and is not covered by Medicare; no other country has formally approved MDMA therapy as of 2026.

Global jurisdiction snapshot (as of 2026):

For a full country-by-country breakdown including Australia’s prescribing data, the April 2026 US executive order, and access routes in Canada and Switzerland, see the dedicated Where Is MDMA Legal? reference page.

In the United States, MDMA is illegal in all 50 states:

• Colorado — Prop 122 decriminalizes psilocybin, DMT, ibogaine, and mescaline for adults 21+. MDMA (Molly/ecstasy) is not included in that list and remains Schedule I under Colorado state law.
• Oregon, California, and all other states — No decriminalization or therapeutic access for MDMA has passed anywhere in the US.

The only legal US access routes are clinical trials (search ClinicalTrials.gov) and FDA Expanded Access for individual patients. See the psychedelic legal status by US state tool for state-by-state context.

How to actually access it

Clinical trials. The MAPS Public Benefit Corporation and Lykos Therapeutics maintain trial listings; additional MDMA trials run through academic centers. Check ClinicalTrials.gov for current recruitment in the United States.

FDA Expanded Access / "compassionate use." Limited pathway for individual patients where no alternative exists; requires treating physician sponsorship and FDA authorization. Small number of patients treated to date.

Australia (residents only). Authorised-prescriber scheme; cost is high and not covered by Medicare.

What not to do. Self-administering MDMA sourced from unregulated supply carries substantial risks — purity variance (especially adulteration with methamphetamine, cathinones, or nothing at all), dose uncertainty, no therapeutic structure, and no ability to respond to medical emergencies. The Phase 3 outcomes should not be assumed to generalize to unmonitored use.

Preparation & integration

The MDMA protocol integrates non-drug therapy sessions directly into treatment — this is not optional and is not a separate product. See the integration therapy guide for what good preparation and post-session work looks like across modalities.